NCT04736589View on ClinicalTrials.gov

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

February 2, 2021

Primary Completion Date

February 2, 2024

Study Completion Date

February 2, 2027

Conditions
Breast Cancer
Interventions
DRUG

Inetetamab

Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.

DRUG

Rapamycin

Oral 2mg, once a day.

DRUG

Pyrotinib

Oral 400mg, once a day.

DRUG

Chemotherapy

Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.

Trial Locations (1)

Unknown

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Peking Union Medical College

OTHER